BRIEF published on 12/04/2025 at 06:35, 5 months 7 days ago Formycon et MS Pharma collaborent pour le biosimilaire de Keytruda® au Moyen-Orient et en Afrique du Nord MS Pharma Keytruda® FYB206 Accord Sur Les Biosimilaires Marché MENA Partenariat Formycon
BRIEF published on 12/04/2025 at 06:35, 5 months 7 days ago Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
PRESS RELEASE published on 12/04/2025 at 06:30, 5 months 7 days ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 5 months 17 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 5 months 17 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 5 months 17 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 5 months 20 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
BRIEF published on 11/20/2025 at 17:05, 5 months 20 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
PRESS RELEASE published on 11/20/2025 at 17:00, 5 months 20 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 5 months 21 days ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
Published on 05/09/2026 at 01:30, 2 days 5 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 7 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/11/2026 at 07:11, 11 minutes ago ams-OSRAM AG: Convocation of the Annual General Meeting 2026
Published on 05/11/2026 at 07:10, 12 minutes ago Readcrest Capital realigns its construction project in Halle
Published on 05/11/2026 at 07:10, 12 minutes ago Hypoport delivered gross profit growth and a marked increase in EBIT at the start of 2026.
Published on 05/11/2026 at 07:08, 14 minutes ago EQS-Adhoc: ams-OSRAM AG: ams OSRAM has published the proposals for the Annual General Meeting 2026
Published on 05/11/2026 at 07:00, 22 minutes ago Aurubis AG: Aurubis delivers improved performance: Increased quarterly result and higher forecast
Published on 05/07/2026 at 19:15, 3 days 12 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 12 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 12 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 12 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 12 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
